Abstract
Renin-angiotensin system inhibitors (RASi), particularly angiotensin-converting enzyme inhibitors (ACEIs) and angiotensin II receptor blockers (ARBs), are commonly used in the treatment of hypertension and are recommended for kidney protection. Uncertainty remains about the effectiveness of RASi being used as first-line antihypertensive therapy on eGFR maintenance compared to its alternatives, especially for those with no or early-stage chronic kidney disease (CKD). We conducted a retrospective cohort study of 19,499 individuals from primary care in Singapore with 4.5 median follow-up years. The study cohort included newly diagnosed individuals with hypertension (whose eGFR was mainly in CKD stages G1-G2) and initiated on ACEIs, ARBs, beta-blockers (BBs), calcium channel blockers (CCBs) or diuretics (Ds) as first-line antihypertensive monotherapy. We compared the eGFR curve before/after the drug initiation over time and analyzed the time to declining to a more advanced stage CKD. Two key findings were observed. First, after initiating antihypertensive drugs, the eGFR almost maintained the same as the baseline in the first follow-up year, compared with dropping 3 mL/min/1.73 m² per year before drug initiation. Second, ARBs were observed to be slightly inferior to ACEIs (HR = 1.14) and other antihypertensive agents (HR = 1.10) in delaying eGFR decline to a more advanced CKD stage. Our results showed that initiating antihypertensive agents can significantly maintain eGFR for those newly diagnosed patients with hypertension. However, RASi may not be superior to other antihypertensive agents in maintaining eGFR levels for non-CKD or early stages CKD patients.
Introduction
Hypertension is a primary driver of Chronic Kidney Disease (CKD). To combat this, clinicians frequently prescribe RASi—specifically ACEIs and ARBs—because they are widely believed to offer superior "renoprotection" compared to other drugs. However, most evidence supporting RASi superiority comes from trials involving patients who already have advanced CKD. There is significant uncertainty regarding whether this advantage holds true for patients in primary care with newly diagnosed hypertension and healthy or only mildly impaired kidney function (CKD stages G1–G2). This study sought to determine if RASi actually outperform alternatives in maintaining the Estimated Glomerular Filtration Rate (eGFR) in a real-world setting.
Methods
The researchers conducted a retrospective cohort study using Electronic Medical Records (EMR) from the SingHealth Polyclinics in Singapore. A "new-user" design was employed, tracking 19,499 adult patients newly diagnosed with hypertension who were initiated on monotherapy.
Patients were divided into three groups: ACEIs, ARBs, and "OTHERS" (Beta-blockers, Calcium Channel Blockers, or Diuretics). To account for confounding by indication, the team used Inverse Probability of Treatment Weighting (IPTW). They analyzed the slope of eGFR change over five years and used Cox proportional hazard regression to determine the time it took for a patient to decline to a more advanced CKD stage.
Key Results
The "Brake" Effect of Medication
Before starting medication, patients’ eGFR declined by an average of 3 mL/min/1.73 m² per year—three times faster than the normal aging process. Immediately after starting any of the five drug classes, this decline was halted, with eGFR stabilizing near baseline in the first year.
RASi Superiority and the ARB Underperformance
For patients with no or early-stage CKD, RASi were not superior to other antihypertensive agents. In fact, the "OTHERS" group showed slightly better eGFR maintenance at the five-year mark than ACEIs or ARBs. Surprisingly, ARBs were found to be slightly inferior to both ACEIs and the "OTHERS" group in delaying progression to more advanced CKD stages.
- Progression Risk: ARBs were associated with a higher risk of progressing to a worse CKD stage compared to ACEIs (Hazard Ratio [HR] = 1.14) and compared to the OTHERS group (HR = 1.10).
- eGFR Maintenance: At the five-year mark, the OTHERS group maintained a higher mean eGFR than the ACEI group and a significantly higher mean than the ARB group.
Discussion and Conclusion
This study provides a real-world reality check on the "gold standard" for kidney protection. While clinical guidelines often prioritize RASi, these findings suggest that for those in the early stages of hypertension, the specific class of drug matters less than the act of starting treatment itself. The priority for clinicians in primary care should be effective blood pressure control rather than a dogmatic preference for RASi in non-CKD populations.
Limitations include the lack of consistent data on albuminuria and lifestyle factors (e.g., salt intake, smoking). Future work should explore the long-term mechanisms behind the unexpected eGFR increase observed in the second year of treatment across all drug classes.
Summary updated